Breast cancer remains the most common cancer in women worldwide, but current treatments are not fully tailored to each patient. We need better models to understand why treatments often don’t work and to find new personalized therapies. Patient-derived organoids (PDOs) are tiny clusters of cells derived from breast cancer patients. They function like miniature versions of the patient’s tumor and help predict how they will respond to treatment. We are using PDOs along with advanced live-cell imaging to study which patients benefit most from CDK4/6 inhibitor treatment and to find new ways to treat those whose cancer resists these drugs. Our aim is to significantly improve personalized breast cancer treatment.
Carla Maria Lourenco Alves
Assistant Professor, SDU